Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 3
2007 1
2009 1
2011 2
2012 2
2014 2
2015 1
2016 1
2017 3
2018 2
2019 6
2020 11
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Results by year
Filters applied: . Clear all
Page 1
Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia.
Berger AA, Keefe J, Winnick A, Gilbert E, Eskander JP, Yazdi C, Kaye AD, Viswanath O, Urits I. Berger AA, et al. Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):617-631. doi: 10.1016/j.bpa.2020.08.010. Epub 2020 Aug 15. Best Pract Res Clin Anaesthesiol. 2020. PMID: 33004171 Review.
Cannabidiol: promise and pitfalls.
Welty TE, Luebke A, Gidal BE. Welty TE, et al. Epilepsy Curr. 2014 Sep;14(5):250-2. doi: 10.5698/1535-7597-14.5.250. Epilepsy Curr. 2014. PMID: 25346628 Free PMC article.
This review highlights some of the basic science theory behind the use of CBD, summarizes published data on clinical use of CBD for epilepsy, and highlights issues related to the use of currently available CBD products. Cannabidiol is the major nonpsychoactive component of …
This review highlights some of the basic science theory behind the use of CBD, summarizes published data on clinical use of CBD for epilepsy …
Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis.
Philpott HT, O'Brien M, McDougall JJ. Philpott HT, et al. Pain. 2017 Dec;158(12):2442-2451. doi: 10.1097/j.pain.0000000000001052. Pain. 2017. PMID: 28885454 Free PMC article.
Osteoarthritis (OA) is a multifactorial joint disease, which includes joint degeneration, intermittent inflammation, and peripheral neuropathy. Cannabidiol (CBD) is a noneuphoria producing constituent of cannabis that has the potential to relieve pain. ...
Osteoarthritis (OA) is a multifactorial joint disease, which includes joint degeneration, intermittent inflammation, and peripheral neuropat …
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.
Booz GW. Booz GW. Free Radic Biol Med. 2011 Sep 1;51(5):1054-61. doi: 10.1016/j.freeradbiomed.2011.01.007. Epub 2011 Jan 14. Free Radic Biol Med. 2011. PMID: 21238581 Free PMC article. Review.
If excessive or unresolved, however, immune-related oxidative stress can initiate further increasing levels of oxidative stress that cause organ damage and dysfunction. Targeting oxidative stress in various diseases therapeutically has proven more problematic than first an …
If excessive or unresolved, however, immune-related oxidative stress can initiate further increasing levels of oxidative stress that cause o …
Is cannabis an effective treatment for joint pain?
Miller RJ, Miller RE. Miller RJ, et al. Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):59-67. Epub 2017 Sep 28. Clin Exp Rheumatol. 2017. PMID: 28967368 Free article. Review.
The major psychotropic component of cannabis is delta9-tetrahydrocannabinol (THC), one of some 120 naturally occurring phytocannabinoids. Cannabidiol (CBD) is another molecule found in herbal cannabis in large amounts. ...However, these reports generally do not extend to r …
The major psychotropic component of cannabis is delta9-tetrahydrocannabinol (THC), one of some 120 naturally occurring phytocannabinoids. …
A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain.
Verrico CD, Wesson S, Konduri V, Hofferek CJ, Vazquez-Perez J, Blair E, Dunner K Jr, Salimpour P, Decker WK, Halpert MM. Verrico CD, et al. Pain. 2020 Sep 1;161(9):2191-2202. doi: 10.1097/j.pain.0000000000001896. Pain. 2020. PMID: 32345916 Clinical Trial.
Over the last 2 decades, affirmative diagnoses of osteoarthritis (OA) in the United States have tripled due to increasing rates of obesity and an aging population. Hemp-derived cannabidiol (CBD) is the major nontetrahydrocannabinol component of cannabis and has been promot …
Over the last 2 decades, affirmative diagnoses of osteoarthritis (OA) in the United States have tripled due to increasing rates of obesity a …
Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study.
Hendricks O, Andersen TE, Christiansen AA, Primdahl J, Hauge EM, Ellingsen T, Horsted TI, Bachmann AG, Loft AG, Bojesen AB, Østergaard M, Lund Hetland M, Krogh NS, Roessler KK, Petersen KH. Hendricks O, et al. BMJ Open. 2019 Jun 4;9(6):e028197. doi: 10.1136/bmjopen-2018-028197. BMJ Open. 2019. PMID: 31167870 Free PMC article.
INTRODUCTION: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic, systemic, inflammatory diseases, primarily in the musculoskeletal system. Pain and fatigue are key symptoms of RA and AS. Treatment presents a clinical challenge for several reasons, inclu …
INTRODUCTION: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic, systemic, inflammatory diseases, primarily in th …
A cautious hope for cannabidiol (CBD) in rheumatology care.
Fitzcharles MA, Clauw DJ, Hauser W. Fitzcharles MA, et al. Arthritis Care Res (Hoboken). 2020 Mar 7. doi: 10.1002/acr.24176. Online ahead of print. Arthritis Care Res (Hoboken). 2020. PMID: 32144889 Review.
Cannabidiol (CBD), a major metabolite of Cannabis sativa, is popularized as a medicinal product, with potential for analgesic, anti-inflammatory and antioxidant effects. CBD may hold promise as a treatment in rheumatic diseases, but evidence to date remains p
Cannabidiol (CBD), a major metabolite of Cannabis sativa, is popularized as a medicinal product, with potential for analgesic, anti-i
Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Mücke M, et al. Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2. Cochrane Database Syst Rev. 2018. PMID: 29513392 Free PMC article. Review.
The studies were 2 to 26 weeks long and compared an oromucosal spray with a plant-derived combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) (10 studies), a synthetic cannabinoid mimicking THC (nabilone) (two studies), inhaled herbal cannabis (two studies) and …
The studies were 2 to 26 weeks long and compared an oromucosal spray with a plant-derived combination of tetrahydrocannabinol (THC) and c
36 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page